Catalog No.
DHA42302
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa
Clonality
Monoclonal
Target
Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A, ANG-2, ANGPT2, Angiopoietin-2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15692 & O15123
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, RG-7221, RG7221, RO5520985, CAS: 1448221-05-3
Clone ID
Vanucizumab
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies, PMID: 33338877
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC), PMID: 32162804
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors, PMID: 29217526
The use of CrossMAb technology for the generation of bi- and multispecific antibodies, PMID: 27285945
Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling, PMID: 27529514
Novel anti-angiogenic therapeutic strategies in colorectal cancer, PMID: 26938715
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment, PMID: 32865652
Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs, PMID: 27863175
Angiopoietin inhibitors: A review on targeting tumor angiogenesis, PMID: 33741382
Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model, PMID: 31394786
For research use only. Not for human or drug use.
